Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 7/20 | 0.45 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624989 | 1.00 | POLB (0.69) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL4999644 | 0.85 | POLB (0.70) | POLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13777929 | 0.83 | POLB (0.64) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL2171944 | 0.82 | POLB (0.70) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL2222163 | 0.80 | POLB (0.63) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL2222173 | 0.80 | POLB (0.63) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL9530359 | 0.79 | POLB (0.62) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL10743630 | 0.79 | POLB (0.62) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL10763278 | 0.78 | POLB (0.61) | POLBMEN1KMT2ASMN1; SMN2NAMPT | |
| SCHEMBL2334270 | 0.76 | MEN1 (0.61) | POLBMEN1KMT2ASMN1; SMN2NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | SCHARPE SIMON LODEWIJK (BE) | 2002-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061839-A1 | Serine peptidase modulators | FAP, CTSC, DPP4 | POLB 3940/4885MEN1 3963/4885KMT2A 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.